Oncology firm Elekta has signed an agreement to purchase radiation therapy firm Nucletron for 365 million euros ($522.1 million U.S.) in cash.
The addition of Nucletron's brachytherapy technology will allow Elekta to offer a complete range of radiation therapy planning and delivery technologies, according to Elekta. It will also add 1,000 new customers to Elekta's current customer base of more than 5,000.
Nucletron had 2010 revenues of 128 million euros ($183.1 million U.S.) and earnings before interest, taxes, depreciation, and amortization (EBITDA) of 26 million euros ($37.2 million U.S.). Elekta expects the transaction will be accretive to its cash earnings within 12 months.
The deal is subject to regulatory approval and is expected to close in early autumn.
